Selenium Supplementation and HIV Patient Health in Rwanda
Author Information
Author(s): Kamwesiga Julius, Mutabazi Vincent, Kayumba Josephine, Tayari Jean-Claude K, Smyth Richard, Fay Heather, Umurerwa Alice, Baziruwiha Marcel, Ntizimira Christian, Murebwayire Antoinette, Haguma Jean Pierre, Nyiransabimana Julienne, Habarurema Donatille, Mukarukundo Veneranda, Nzabandora Jean Bosco, Nzamwita Pascal, Mukazayire Ernestine, Mills Edward J, Seely Dugald, McCready Douglas J, Warren Don
Primary Institution: Rwanda Selenium Supplementation Clinical Trial Team, Kigali, Rwanda
Hypothesis
Selenium supplementation in pre-ART patients will improve CD4 cell counts, decrease opportunistic infections, decrease HIV viral load, and delay ART initiation.
Conclusion
Selenium supplementation may improve health outcomes for HIV-infected patients in resource-constrained settings like Rwanda.
Supporting Evidence
- Low serum selenium levels are linked to higher mortality risk in HIV+ patients.
- Micronutrient deficiencies can worsen HIV disease progression.
- Previous trials have shown mixed results on selenium's effects on HIV health.
Takeaway
This study is testing if giving selenium to HIV patients can help them stay healthier for longer before they need stronger treatments.
Methodology
A 24-month, multi-centre, patient and provider-blinded, randomized, placebo-controlled clinical trial.
Potential Biases
Potential biases may arise from the blinding process and participant selection.
Limitations
The study may not be generalizable to all HIV-infected populations due to its specific setting and participant criteria.
Participant Demographics
HIV-infected adults aged 21 and older, with CD4 counts between 400-650 cells/mm3, not yet on ART.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website